Ultrasound Brain Disease Device Startup SonoCare Lab Raises Seed Funding from Bluepoint Partners


SonoCare Lab, a startup developing ultrasound-based medical devices for brain disease, has raised Seed funding from deep tech accelerator Bluepoint Partners.

Ultrasound Brain Disease Device Startup SonoCare Lab Raises Seed Funding from Bluepoint Partners

The investment size and valuation were not disclosed.

SonoCare Lab was founded on brain-therapy ultrasound technology that Professor Jinhyung Park of Sungkyunkwan University’s Department of Global Biomedical Engineering accumulated while carrying out a Samsung Research Funding & Incubation Center project.

Alzheimer’s treatment has reached a turning point with the arrival of antibody therapies such as lecanemab and donanemab, which target amyloid beta. SonoCare Lab, however, believes that raising treatment efficacy further will require addressing not only the drugs but also the process by which waste leaves the brain.

The company is focused on the brain’s own “cleaning system.” The glymphatic system is involved in clearing metabolic waste through the circulation of cerebrospinal fluid (CSF) and interstitial fluid. SonoCare Lab is developing a medical device that directly modulates this system with ultrasound.

Its core technology, the Acoustic Brain Sweeper, promotes this circulation through a proprietary sweeping technique that moves ultrasound in a set direction. It works by applying physical stimulation along the pathways through which waste exits the brain, activating the clearance function.

The company plans to develop the technology as a companion device to be used alongside antibody therapies, aiming to improve treatment efficiency by assisting waste clearance.

Park, CEO of SonoCare Lab, earned a doctorate in biomedical engineering from the University of Southern California for his work on ultrasound technology development. He then handled ultrasound system development and commercialization at Siemens’ ultrasound research lab in Korea and at Philips in the United States. He started the company to combine the commercialization experience he built at global firms with the lab’s core technology.

Suyong Park, Director at Bluepoint, who handled the investment, said central nervous system diseases, including Alzheimer’s, remain an area of significant unmet medical need that requires new therapeutic approaches beyond drug treatment. “SonoCare Lab is a team with a differentiated technology that non-invasively modulates the brain’s waste-clearance mechanism, built on its long-accumulated capabilities in developing ultrasound medical devices,” he said.

Jinhyung Park said the goal is to add the brain’s own waste-clearance system to the shift in Alzheimer’s treatment that began with antibody therapies. “Based on our experience developing ultrasound medical devices, we will first enter the market for companion devices to antibody therapies, and in the long term grow into a platform used together with treatments for a range of central nervous system diseases,” he said.

Share

Leave a Reply

Your email address will not be published. Required fields are marked *